BioMedReports

LOS ANGELES, CA -- (Marketwired) -- 05/08/13 -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has seen its stock rise from about $5.25 per share in February at the time of the NASDAQ listing to around $9 per share and is one of the best performing stocks in the biotech industry ... read more

LOS ANGELES, CA -- (Marketwired) -- 05/08/13 -- Pluristem (NASDAQ: PSTI) recently announced a new Phase I trial to check safety and evaluate effectiveness of its PLX-PAD cells in chronic tendonitis often leading to rotator cuff disorders, common in tennis players and golfers, where there are roughly 200,000 rotator ... read more

LOS ANGELES, CA -- (Marketwired) -- 05/07/13 -- When Tauriga Sciences, Inc. (OTCQB: TAUG) CEO, Seth Shaw, took the job in August of 2012 his mission was to advance an underperforming company that held licensing rights to a promising immunotherapeutic drug for cancer patients. Tauriga was called Immunovative, Inc. ... read more

LOS ANGELES, CA -- (Marketwired) -- 04/24/13 -- In newly published news, CEL-SCI Corporation (NYSE MKT: CVM) has provided investors a much needed update on the Phase III Clinical Trial of its investigational drug Multikine. We perceive this as a bullish advancement for several reasons. Some may recall that in early ... read more

LOS ANGELES, CA -- (Marketwired) -- 04/22/13 -- In a newly published Expert Briefing which appears at BioMedReports, David Platt, Ph.D., CEO of Manchester, NH-based Boston Therapeutics (OTCQB: BTHE), writes that Carbohydrates have been shown to play a fundamental role in normal cell functions as well as in major ... read more

LOS ANGELES, CA -- (Marketwired) -- 04/04/13 -- Anyone who has ever had a family member or friend afflicted with cancer knows first hand that the treatments they must endure seem far more devastating than the disease itself. An exciting video released by CEL-SCI (NYSE Amex: CVM) earlier this ... read more

LOS ANGELES, CA -- (Marketwire) -- 03/14/13 -- A handful of early investors are fighting an uphill battle after investing in shares of AntriaBio (OTCBB: ANTB), which recently swooped in to snag an intriguing lead diabetes product, AB101, after a private firm had already invested more than $100 million ... read more

LOS ANGELES, CA -- (Marketwire) -- 02/19/13 -- DARA Biosciences (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, is expecting to hear soon on the status of its Orphan Drug application submitted to The Food and Drug Administration (FDA) in November of ... read more

LOS ANGELES, CA -- (Marketwire) -- 02/06/13 -- While trading catalyst driven small cap biotechs can be risky, if executed with discipline and closely monitored technical chart analysis, these types of trades can offer rewarding returns to investors. Along with the rest of the market, a few of our recent ... read more

LOS ANGELES, CA -- (Marketwire) -- 01/29/13 -- Our focus turns to EnteroMedics, which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics' approach may be a better solution for people who see little or no benefit from current ... read more

LOS ANGELES, CA -- (Marketwire) -- 01/22/13 -- In 2012, many stem cell stocks experienced fast-paced growth as new and promising research continues to propel the industry forward. Last July, we first wrote about Pluristem Therapeutics (NASDAQ: PSTI), a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products ... read more

LOS ANGELES, CA -- (Marketwire) -- 01/15/13 -- BioLineRx engages in identifying, in-licensing, and developing therapeutic candidates. Its lead clinical therapeutic candidate under development is BL-1020, which is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients. BL-1020 is an orally available, first in class ... read more

LOS ANGELES, CA -- (Marketwire) -- 12/19/12 -- Neptune Technologies & Bioresources, Inc. (NASDAQ: NEPT) has seen its stock fall 45% from its closing price on November 7th. On December 8th, Neptune suffered a tragedy, in which their manufacturing facility and inventory were completely destroyed in an explosion that ... read more

LOS ANGELES, CA -- (Marketwire) -- 09/06/12 -- A new detailed report focused on NovaBay Pharmaceuticals (NYSE MKT: NBY) by biotech columnist Scott Matusow sheds light on the big board listed, emerging biotech firm which is developing two distinct anti-infective product lines led by NVC-422 and NeutroPhase R -- ... read more

LOS ANGELES, CA -- (Marketwire) -- 04/19/12 -- In an exclusive Expert Briefing at BioMedReports, Yuichi Iwaki, M.D., Ph.D., the Founder, President and Chief Executive Officer of MediciNova, Inc. (NASDAQ: MNOV) tells investors about a promising treatment approach aimed at meeting the need for novel treatments for patients ... read more

LOS ANGELES, CA -- (Marketwire) -- 04/17/12 -- In what is seen as a game changing event for the company, TapImmune (OTCBB: TPIV) announced on Monday that it had signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester, MN, to License a proprietary MHC ... read more

LOS ANGELES, CA -- (Marketwire) -- 04/09/12 -- Last month, Aastrom Biosciences, Inc. (NASDAQ: ASTM) announced that it had completed an impressive, $40 million private placement financing. The development was noted as a particularly bullish sign for emerging biotechs everywhere. In an exclusive interview, Timothy Mayleben, who has served ... read more

LOS ANGELES, CA -- (Marketwire) -- 04/04/12 -- Trading on the Euronext, Pharming Group NV (EURONEXT: PHARM) produces, purifies and formulates recombinant human proteins using its transgenic technology platform for therapeutic indications in Hereditary Angioedema, Transplant Rejection, Blood Coagulation Disorders and Ischemic Reperfusion Injury. Pharming Group develops products for ... read more

LOS ANGELES, CA -- (Marketwire) -- 03/06/12 -- Exact Sciences Corporation (NASDAQ: EXAS), the molecular diagnostics company focused on colorectal cancer, has been steadily inching towards their commercialization goals and one need only look at their stock chart to see the steady, reliable advancement. In fact, inch by inch, ... read more

LOS ANGELES, CA -- (Marketwire) -- 03/01/12 -- On Wednesday, EpiCept Corporation (OTCQX: EPCT) (PINKSHEETS: EPCT) was among a short list of U.S. companies reported by Bloomberg as having reported positive surprises or matched expectations. This after company officials announced operating and financial results for the fourth quarter ... read more